Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 13/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 4/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.39 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | USP8 | P40818 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15209104 | 0.83 | MAPKAPK2 (0.48) | PIM1ACVR1TGFBR1CCNT1CDK9 | |
| SCHEMBL15216705 | 0.82 | CHEK1 (0.47) | PIM1ACVR1TGFBR1CDK9BMPR1B | |
| SCHEMBL723929 | 0.82 | PIM1 (0.50) | PIM1ACVR1TGFBR1BMPR1BBMPR1A | |
| SCHEMBL725211 | 0.80 | CCNC (0.40) | FLT3 | |
| SCHEMBL30765389 | 0.80 | NMT1 (0.49) | — | |
| SCHEMBL723000 | 0.79 | ACVR1 (0.47) | ACVR1TGFBR1CCNT1CDK9BMPR1B | |
| SCHEMBL725130 | 0.79 | PIK3C3 (0.36) | CDK2 | |
| SCHEMBL722250 | 0.78 | ACVR1 (0.51) | PIM1ACVR1TGFBR1CCNT1CDK9 | |
| SCHEMBL721482 | 0.78 | ACVR1 (0.44) | PIM1ACVR1TGFBR1CCNT1CDK9 | |
| SCHEMBL723677 | 0.78 | TNKS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | claimed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | PIM1 404/4885ACVR1 2178/4885TGFBR1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.